Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
- Partnership with major healthcare network Hoag expands market reach and accessibility of EsoGuard test
- Strategic positioning as a model for future healthcare system partnerships
- Integration into multiple medical programs (digestive health, primary care, concierge medicine) increases potential test volume
- Addresses growing medical need with esophageal cancer cases increasing tenfold in past 40 years
- None.
Insights
Hoag partnership brings LUCD's EsoGuard test to a major California health network, potentially accelerating adoption and revenue growth.
Lucid Diagnostics' new partnership with Hoag represents a significant commercial milestone in the company's growth strategy. This collaboration with a nationally-recognized healthcare network will integrate EsoGuard esophageal precancer testing across Hoag's digestive health, primary care, and concierge medicine programs throughout Orange County, California.
The strategic importance of this deal cannot be overstated. Healthcare system adoption represents the most efficient pathway to scale for diagnostic products like EsoGuard. Rather than pursuing individual physician adoption, this partnership instantly provides access to Hoag's extensive network of providers and patients. The endorsement from Dr. Kenneth Chang, a respected authority in gastroenterology, adds substantial clinical credibility to EsoGuard's value proposition.
From a market development perspective, this agreement creates a blueprint for future health system partnerships. CEO Aklog specifically mentions this collaboration serving as a model for additional leading health systems, suggesting a deliberate strategy to leverage this initial partnership into a broader institutional adoption campaign.
The partnership addresses a critical clinical need with significant market potential. With esophageal cancer incidence having increased tenfold over four decades according to the release, EsoGuard's 3-minute non-endoscopic test offers an accessible screening method for a condition that typically lacks early detection. Hoag's comprehensive approach to integrating the test across multiple clinical settings (specialty, primary care, and concierge) demonstrates the product's versatility across different care delivery models.
For investors, this represents tangible commercial progress for Lucid's go-to-market strategy, potentially accelerating revenue growth through increased test volumes within a major regional health system.
Lucid to partner with Hoag in its mission to eradicate esophageal cancer by expanding access to EsoGuard precancer testing across its extensive healthcare delivery network
"This is a game changer in our mission towards achieving an esophageal cancer-free
"We are thrilled to partner with a renowned, world-class healthcare system like Hoag," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "It's always great to find partners such as Dr. Chang and his colleagues who share our mission to eliminate the scourge of esophageal cancer. This partnership also represents an important milestone in expanding access to EsoGuard within large healthcare systems, and we expect our collaboration with Hoag will serve as a model for additional leading health systems to offer EsoGuard testing across their healthcare delivery networks."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
About Hoag
Hoag is a nonprofit regional health care delivery system in
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/major-california-health-system-launches-comprehensive-esophageal-precancer-testing-program-using-lucid-diagnostics-esoguard-esophageal-dna-test-302485434.html
SOURCE Lucid Diagnostics
FAQ
What is the significance of Lucid Diagnostics' partnership with Hoag for LUCD stock?
What is Lucid Diagnostics' EsoGuard test and how does it work?
How will the Hoag partnership affect Lucid Diagnostics' market reach?
Why is Lucid Diagnostics' EsoGuard test important for healthcare?
Who are the key executives involved in the Lucid Diagnostics-Hoag partnership?
